DK2170860T5 - Benzimidazolderivater - Google Patents
Benzimidazolderivater Download PDFInfo
- Publication number
- DK2170860T5 DK2170860T5 DK08762901.0T DK08762901T DK2170860T5 DK 2170860 T5 DK2170860 T5 DK 2170860T5 DK 08762901 T DK08762901 T DK 08762901T DK 2170860 T5 DK2170860 T5 DK 2170860T5
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- benzimidazol
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Forbindelse med formel ll(a),
hvor: hvert R1 uafhængigt er halogen, (Ci-C6)alkyl, (CrC6)alkoxy, -CF3, -CN, eller-NR16R17; R2 er hydrogen eller (CrC6)alkyl; R3B er hydrogen, (CrC6)alkyl, -(CH2)t(C6-Ci2)aryl, eller -(CH2)t(C3-Ci2)carbocyclyl; R4 er hydrogen eller (CrC6)alkyl; R10 er -(CH2)t(C6-Ci2)aryl eller -(CH2)t(4- til 14-leddet heterocyclyl), hvor hvert af (C6-C-|2)arylet og (det 4- til 14-leddede heterocyclyl) eventuelt er substitueret med fra 1 til 5 substituenter, hvoraf hver uafhængigt er udvalgt fra (Cr C6)alkyl, - CN, halogen, -CF3, -OCF3, -NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-Ci2aryl), -C(0)(Ci-C6 alkyl), -C(0)CF3, azido, (4- til 12-leddet heterocyclyl) og -S((CrC6)alkyl); hvert R16 og R17 uafhængigt er udvalgt fra hydrogen og (Ci-C6)alkyl; n er 0, 1,2, 3 eller 4; og hvert t uafhængigt er 0, 1 eller 2; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor: hvert R1 uafhængigt er F, Cl, Br, -CH3, -OCH3, -CF3, -CN eller -NR16R17; R2 er hydrogen; R3B er hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3,-CH2CH(CH3)2 eller -CH2(phenyl); R4 er hydrogen; og R10 er phenyl, pyridyl eller 2,3-dihydro-1,4-benzodioxinyl, hvor hvert af phe-nylet, pyridylet og 2,3-dihydro-1,4-benzodioxinylet eventuelt er substitueret med fra 1 til 5 substituenter, hvoraf hver uafhængigt er udvalgt fra (Cr C6)alkyl, -CN, halogen,-CF3, -OCF3, -NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-Ci2)aryl, -C(0)(CrC6 alkyl),-C(0)CF3, azido, (4- til 12-leddet hete-rocyclyl) og -S((CrC6)alkyl); eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 2, hvor: hvert R1 uafhængigt er F, Cl, -CH3, -OCH3, -CF3, -CN eller -N(CH3)2; R3B er -CH3; og R10 er phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl eller 2,3-dihydro-1,4-benzodioxin-6-yl, hvor hvert af phenylet, 2-pyridylet, 3-pyridylet, 4-pyridylet og 2,3-dihydro-1,4-benzodioxin-6-ylet eventuelt er substitueret med fra 1 til 5 substituenter, hvoraf hver uafhængigt er udvalgt fra (CrC6)alkyl, -CN, halogen, -CF3, -OCF3, -NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-C12)aryl, -CfOJfCrCe alkyl), -C(0)CF3, azido, (4- til 12-leddet heterocyclyl) og -S((CrC6)alkyl); eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 3, hvor R10 er phenyl, 3-pyridyl eller 2,3-dihydro-1,4-benzodioxin-6-yl, hvor hvert af phenylet, 3-pyridylet og 2,3-dihydro-1,4-benzodioxin-6-ylet eventuelt er substitueret med fra 1 til 5 substituenter hvoraf hver uafhængigt er udvalgt fra (CrC6)alkyl, -CN, halogen, -CF3, -OCF3, NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-Ci2)aryl, -C(0)(CrC6 alkyl), -C(0)CF3, azido, (4- til 12-leddet heterocyclyl), og -S((CrC6)alkyl); eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge krav 4, hvor R10 er phenyl eventuelt substitueret med fra 1 til 5 substituenter, hvoraf hver uafhængigt er udvalgt fra (CrC6)alkyl, -CN, halogen, -CF3, -OCF3, -NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-C12)aryl, -C(0)(CrC6 alkyl), -C(0)CF3, azido, (4- til 12-leddet heterocyclyl) og -S((Cr C6)alkyl); eller et farmaceutisk acceptabelt salt deraf.
6. Forbindelse ifølge krav 5, hvor R10 er phenyl eventuelt substitueret med fra 1 til 5 substituenter, hvoraf hver uafhængigt er udvalgt fra - CH3, -CN, -F, -Cl, -Br, -CF3, -OCF3, -NR16R17, -OCH3 og -N02; eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 1, som er en forbindelse med formel IV(a)
hvor: hvert R1 uafhængigt er halogen, (Ci-C6)alkyl, (Ci-C6)alkoxy, -CF3, -CN eller -NR16R17; R2 er hydrogen eller (CrC6)alkyl; R3B er hydrogen, (CrCeJalkyl, -(CH2)t(C6-Ci2)aryl eller -(CH2MC3-Ci2)carbocyclyl; R4 er hydrogen eller (CrC6)alkyl; hvert R12 uafhængigt er udvalgt fra (C-i-C6)alkyl, -CN, halogen, -CF3, -OCF3, -NR16R17, (CrC6)alkoxy, -N02, -(CH2)t(C6-Ci2)aryl, -C(0)(CrC6alkyl), -C(0)CF3, azido, (4- til 12-leddet heterocyclyl) og -S((Ci-C6)alkyI); hvert R16 og R17 uafhængigt er udvalgt fra hydrogen og (CrC6)alkyl; n er 0,1,2, 3 eller 4; hvert t uafhængigt er 0,1 eller 2; og z er 0,1,2, 3, 4 eller 5; eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge krav 7, hvor: R2 er hydrogen; R3B er -CH3; R4 er hydrogen; og hvert R12 uafhængigt er udvalgt fra -CN, -F, -Cl, -Br, -CF3, -OCF3, -NR16R17--OCH3 og -N02; eller et farmaceutisk acceptabelt salt deraf.
9. Forbindelse ifølge krav 8, hvor: hvert R1 uafhængigt er halogen, -CH3, -OCH3, -CF3, -CN eller -N(CH3)2; R12 er -CN, -F, -Cl, -Br, -CF3, -OCF3, -OCH3 eller -N02; og z er 1; eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge krav 9, hvor: R12 er -CN, -F, -Cl, -Br eller -CF3; og n er 0; eller et farmaceutisk acceptabelt salt deraf.
11. Forbindelse ifølge krav 10, hvor R12 er -CN eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge krav 1, udvalgt fra: 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -methylpiperidin-4-yl]-3-(4-cyanophenyl)urinstof; 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -methylpiperidin-4-yl]-3-(4-chlorophenyl)urinstof; 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -methylpiperidin-4-yl]-3-(6-fluorpyridin-3-yl)urinstof; 1 -{(2R,4R)-1 -methyl-2-[5-(trifluormethyl)-1 H-benzimidazol-2-yl]piperidin-4-yl}-3-[6-(trifluormethyl)pyridin-3-yl]urinstof; 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -methylpiperidin-4-yl]-3-(4-methoxyphenyl)urinstof; 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -isobutylpiperidin-4-yl]-3-(4-cyanophenyl)urinstof; og 1 -[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1 -methylpiperidin-4-yl]-3-(6-fluor-5-methylpyridin-3-yl)urinstof; eller et farmaceutisk acceptabelt salt deraf.
13. Forbindelse ifølge krav 1, som er 1-[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urinstof eller et farmaceutisk acceptabelt salt deraf.
14. Forbindelse ifølge krav 13, som er et farmaceutisk acceptabelt salt af 1-[(2R,4R)-2-(1 H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urinstof.
15. Farmaceutisk sammensætning, omfattende en forbindelse ifølge et af kravene 1 til 14, eller et farmaceutisk acceptabelt salt deraf og en farmaceutisk acceptabel adjuvans, fortynder eller bærer.
16. Anvendelse af en forbindelse ifølge et af kravene 1 til 14 eller et farmaceutisk acceptabelt salt deraf inden for fremstillingen af et medikament til behandling af abnorm cellevækst, fortrinsvis kræft, i et pattedyr.
17. Forbindelse ifølge et af kravene 1 til 14 eller et farmaceutisk acceptabelt salt deraf til anvendelse inden for behandlingen af abnorm cellevækst, fortrinsvis kræft, i et pattedyr.
18. Kombination af en forbindelse ifølge et af kravene 1 til 14 eller et farmaceutisk acceptabelt salt deraf og et andet anti-tumorstof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94728707P | 2007-06-29 | 2007-06-29 | |
| US4164508P | 2008-04-02 | 2008-04-02 | |
| PCT/IB2008/001575 WO2009004427A2 (en) | 2007-06-29 | 2008-06-16 | Benzimidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2170860T3 DK2170860T3 (da) | 2017-01-09 |
| DK2170860T5 true DK2170860T5 (da) | 2017-03-20 |
Family
ID=40161351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08762901.0T DK2170860T5 (da) | 2007-06-29 | 2008-06-16 | Benzimidazolderivater |
Country Status (46)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2170860T (pt) * | 2007-06-29 | 2017-01-04 | Pfizer | Derivados de benzimidazol |
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| RU2533825C2 (ru) * | 2009-06-11 | 2014-11-20 | Сиена Байотек С.П.А. | ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG |
| CA2771833A1 (en) | 2009-08-26 | 2011-03-03 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
| JP5452459B2 (ja) | 2010-12-16 | 2014-03-26 | 株式会社Ｎｔｔドコモ | ホーム基地局及びハンドオーバ方法 |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| DK2680694T3 (da) | 2011-02-28 | 2019-03-25 | Biomarin Pharm Inc | Histondeacetylasehæmmere |
| EP2684167B1 (en) | 2011-03-08 | 2020-09-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| FR2980477B1 (fr) | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
| EP2844648B1 (en) * | 2011-09-26 | 2016-11-09 | Merck Patent GmbH | Benzyl piperidine compounds as lysophosphatidic acid (lpa) receptor antagonist |
| US20150133450A1 (en) | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US10029988B2 (en) | 2013-03-15 | 2018-07-24 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
| EP2996689A1 (en) * | 2013-04-17 | 2016-03-23 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| GB2519344A (en) * | 2013-10-18 | 2015-04-22 | Redx Pharma Ltd | Compounds |
| US10640803B2 (en) | 2013-10-30 | 2020-05-05 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| MX2017013645A (es) * | 2015-04-24 | 2018-03-08 | Pfizer | Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-me tilpiperidin-4-il)-3-(4-cianofenil)urea maleato. |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP2020164722A (ja) * | 2019-03-29 | 2020-10-08 | デクセリアルズ株式会社 | 接着剤組成物 |
| US20230107634A1 (en) | 2020-01-28 | 2023-04-06 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof |
| CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| EP4126237B1 (en) | 2020-03-26 | 2024-04-10 | LEK Pharmaceuticals d.d. | Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea |
| US20230301950A1 (en) | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| WO2023002362A1 (en) | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Treatment of hematological malignancy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL366799A1 (en) | 2001-07-27 | 2005-02-07 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CA2473892C (en) | 2001-12-04 | 2010-09-21 | Actelion Pharmaceuticals Ltd | Novel quinoline derivatives |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| JP2006505570A (ja) | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
| WO2005042495A1 (en) | 2003-10-21 | 2005-05-12 | Imclone Systems Incorporated | (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity |
| US7309716B2 (en) | 2003-10-28 | 2007-12-18 | Vertex Pharmaceuticals Incorporated | Benzimidazoles useful as modulators of ion channels |
| EP1807074B1 (en) * | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| DE102005012875B4 (de) * | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
| WO2006124780A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| WO2008064830A1 (en) | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses |
| CA2672815A1 (en) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Benzimidazole derivatives for use in treating abnormal cell growth |
| PT2170860T (pt) * | 2007-06-29 | 2017-01-04 | Pfizer | Derivados de benzimidazol |
| EP2303275A4 (en) | 2008-06-17 | 2012-05-09 | Univ Duke | STANDARD RECEPTOR MODULATORS |
| ES2797955T3 (es) | 2008-08-25 | 2020-12-04 | Novartis Ag | Moduladores de la ruta de hedgehog |
-
2008
- 2008-06-16 PT PT87629010T patent/PT2170860T/pt unknown
- 2008-06-16 GE GEAP200811622A patent/GEP20125702B/en unknown
- 2008-06-16 PL PL08762901T patent/PL2170860T3/pl unknown
- 2008-06-16 ME MEP-2009-349A patent/ME00962B/me unknown
- 2008-06-16 EP EP08762901.0A patent/EP2170860B9/en active Active
- 2008-06-16 DK DK08762901.0T patent/DK2170860T5/da active
- 2008-06-16 SI SI200831707A patent/SI2170860T1/sl unknown
- 2008-06-16 CN CN200880022602XA patent/CN101687841B/zh active Active
- 2008-06-16 JP JP2010514162A patent/JP4567099B2/ja active Active
- 2008-06-16 AP AP2009005089A patent/AP2377A/xx active
- 2008-06-16 AU AU2008272641A patent/AU2008272641B2/en active Active
- 2008-06-16 CA CA2690953A patent/CA2690953C/en active Active
- 2008-06-16 EA EA200971104A patent/EA016888B1/ru unknown
- 2008-06-16 ES ES08762901.0T patent/ES2609258T3/es active Active
- 2008-06-16 BR BRPI0813412A patent/BRPI0813412B8/pt active IP Right Grant
- 2008-06-16 RS RS20161132A patent/RS55395B9/sr unknown
- 2008-06-16 KR KR1020107001991A patent/KR101143246B1/ko active IP Right Grant
- 2008-06-16 HU HUE08762901A patent/HUE030052T4/en unknown
- 2008-06-16 LT LTEP08762901.0T patent/LT2170860T/lt unknown
- 2008-06-16 WO PCT/IB2008/001575 patent/WO2009004427A2/en active Application Filing
- 2008-06-16 MY MYPI20095266A patent/MY148636A/en unknown
- 2008-06-16 NZ NZ581889A patent/NZ581889A/en unknown
- 2008-06-19 PA PA20088785401A patent/PA8785401A1/es unknown
- 2008-06-19 US US12/142,119 patent/US8148401B2/en active Active
- 2008-06-20 UY UY31164A patent/UY31164A1/es active IP Right Grant
- 2008-06-25 HN HN2008000974A patent/HN2008000974A/es unknown
- 2008-06-27 CL CL2008001922A patent/CL2008001922A1/es unknown
- 2008-06-27 TW TW097124392A patent/TWI371451B/zh active
- 2008-06-27 AR ARP080102792A patent/AR067346A1/es active IP Right Grant
- 2008-06-27 PE PE2012000473A patent/PE20121010A1/es active IP Right Grant
- 2008-06-27 PE PE2008001105A patent/PE20090772A1/es active IP Right Grant
-
2009
- 2009-11-30 IL IL202420A patent/IL202420A/en active IP Right Grant
- 2009-12-07 CR CR11150A patent/CR11150A/es unknown
- 2009-12-08 DO DO2009000278A patent/DOP2009000278A/es unknown
- 2009-12-14 EC EC2009009803A patent/ECSP099803A/es unknown
- 2009-12-18 NI NI200900219A patent/NI200900219A/es unknown
- 2009-12-21 CU CU2009000225A patent/CU23847B1/es active IP Right Grant
- 2009-12-21 GT GT200900328A patent/GT200900328A/es unknown
- 2009-12-23 CO CO09147462A patent/CO6160232A2/es unknown
- 2009-12-25 TN TNP2009000544A patent/TN2009000544A1/fr unknown
- 2009-12-29 MA MA32454A patent/MA31466B1/fr unknown
-
2010
- 2010-06-09 HK HK10105659.9A patent/HK1139658A1/xx unknown
- 2010-08-04 JP JP2010175465A patent/JP2010280693A/ja active Pending
-
2012
- 2012-02-24 US US13/404,169 patent/US8431597B2/en active Active
-
2016
- 2016-11-23 HR HRP20161562TT patent/HRP20161562T2/hr unknown
- 2016-12-14 CY CY20161101293T patent/CY1118650T1/el unknown
-
2020
- 2020-07-15 NL NL301057C patent/NL301057I2/nl unknown
- 2020-08-11 NO NO2020027C patent/NO2020027I1/no unknown
- 2020-08-12 CY CY2020028C patent/CY2020028I2/el unknown
- 2020-08-13 HU HUS2000031C patent/HUS2000031I1/hu unknown
- 2020-08-20 FR FR20C1038C patent/FR20C1038I2/fr active Active
- 2020-08-26 LT LTPA2020528C patent/LTC2170860I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2170860T5 (da) | Benzimidazolderivater | |
| US20100029615A1 (en) | Benzimidazole derivatives | |
| CA2813162C (en) | Pyridine-2- derivatives as smoothened receptor modulators | |
| US20120157471A1 (en) | Benzimidazole derivatives | |
| AU2014351433B2 (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |